GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is Betting Billions He Can Do It Again copertina

GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is Betting Billions He Can Do It Again

GLP-1s Took Eli Lilly To $1 Trillion. CEO Dave Ricks Is Betting Billions He Can Do It Again

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.
A proposito di questo titolo
 As CEO of the largest, most successful drugmaker on the planet, Dave Ricks sure spends a lot of time thinking about risk. Eli Lilly’s weight-loss and diabetes drugs have become wildly successful beyond anyone’s imagination. Its latest 12-month revenue (through June 30) surged 50% to $79.7 billion, with Zepbound (for weight loss) and Mounjaro (for diabetes) accounting for 62% of the total. In November 2025, its market cap crossed the $1 trillion mark, making it the first pharma company to do so (it’s currently hovering around $1.1 trillion). Lilly has more weight-loss game-changers coming. A pill called Foundayo gained FDA approval in April. It plans to submit a next-gen experimental drug, retatrutide, to the FDA in the first quarter of 2027. (People are so excited about “reta,” as it’s called online, that they’re buying substances claiming to be the drug on the black market.) But the clock is ticking. All drugs have a shelf life because of how pharma patents work. Likely at some point in the 2030s, the exploding market for its weight-loss drugs will collapse as generics flood in. Read the full story on Forbes: https://www.forbes.com/sites/amyfeldman/2026/10/15/glp-1s-took-eli-lilly-to-1-trillion-ceo-dave-ricks-is-betting-billions-he-can-do-it-again/ Learn more about your ad choices. Visit megaphone.fm/adchoices
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione